Skip to main content

Table 2 The baseline characteristics at diagnosis of MDS patients with MF-2/3 (n = 43)

From: Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome

 

Transplant (n = 20)

Non-transplant (n = 23)

P

Age (years), median, range

42 (27–60)

58 (21–79)

0.003

Gender, no. (%)

0.106

 Male

10 (50.0%)

17 (73.9%)

 

 Female

10 (50.0%)

6 (26.1%)

 

Median WBC (range), × 109/L

2.73 (1.10–12.00)

2.91 (1.34–7.36)

0.759

Median NE (range), × 109/L

0.85 (0.04–2.27)

0.92 (0.16–4.92)

0.439

Median HGB (range), g/L

65 (30–138)

69 (36–84)

0.706

Median PLT (range), × 109/L

41.5 (3–234)

82 (8–282)

0.179

MDS subtypes (WHO, 2016), no. (%)

0.290

 MDS-SLD

2 (10.0%)

0 (0.0%)

 

 MDS-MLD

3 (15.0%)

1 (4.3%)

 

 MDS-RS-SLD

0 (0.0%)

2 (8.7%)

 

 MDS-RS-MLD

1 (5.0%)

2 (8.7%)

 

 MDS with isolated 5q-deletion

0 (0.0%)

0 (0.0%)

 

 MDS-EB-1

5 (25.0%)

5 (21.8%)

 

 MDS-EB-2

8 (40.0%)

13 (56.5%)

 

 MDS-U

1 (5.0%)

0 (0.0%)

 

Cytogenetic

0.692

 Normal karyotype

5 (25.0%)

7 (30.4%)

 

 Aberrant karyotype

15 (75.0%)

16 (69.6%)

 

IPSS-R risk group, no. (%)

0.128

 Very low

0 (0.0%)

0 (0.0%)

 

 Low

2 (10.0%)

3 (13.0%)

 

 Intermediate

7 (35.0%)

2 (8.7%)

 

 High

6 (30.0%)

6 (26.1%)

 

 Very high

5 (25.0%)

12 (52.2%)

 

Treatment, no. (%)

 Cytoreductive treatments pre-transplantation

11 (55.0%)

0 (0.0%)

 

 Cytoreductive treatments without HSCT

0 (0.0%)

12 (52.2%)

 

 Immunoregulatory

0 (0.0%)

5 (21.7%)

 

 Supportive care

0 (0.0%)

6 (26.1%)

 

Leukemia transformation, no. (%)

6 (30.0%)

2 (8.3%)

0.115

Median time from diagnosis to leukemia transformation, months (range)

7 (1–20)

12 (9–15)

0.249